IGES at the health economics conference ISPOR Europe 2024 in Barcelona
The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on the benefit assessment of orphan drugs in Germany. ISPOR Europe 2024 will take place from November 17 to 20 in Barcelona.
Berlin, 13. November 2024 (IGES Institut) - HTA harmonisation in Europe is one of the most far-reaching changes in EU pharmaceutical legislation since the introduction of centralised marketing authorisation around two decades ago. It will see the gradual introduction of a joint clinical assessment of new medicines at EU level from 1 January 2025.
As stakeholders, the two IGES companies IGES Institut and Basel-based HealthEcon AG have contributed to the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities. Participating experts will be present at ISPOR.
In the area of analyses of the pharmaceutical market, IGES experts will present studies on benefit assessments under the German Act on the Reform of the Market for Medicinal Products (AMNOG). Among other things, they will show which factors influence the therapy costs of orphan drugs when they undergo another benefit assessment procedure in Germany due to exceeding a sales threshold. They also describe how the added benefit changes when a new procedure is carried out as a result of a late label extension.
The IGES Group offers a wide range of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support all phases of the product life cycle management of new developments. They are geared towards the most important European healthcare markets.
ISPOR is the world's leading organization for health economics and outcomes research (HEOR). The congress, which takes place in Barcelona from November 17 to 20, is one of the organization's largest annual events. The IGES Group has been contributing to the ISPOR program for many years.
IGES at ISPOR: HTA, Market Access and Strategy in Europe, EU-HTA Stakeholder.
Booth 620
Barcelona International Convention Center
Placa de Willy Brandt, 11-14, 08019
Barcelona, Spain
Posterpräsentationen:
Brückel S, Reindl S
Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessment of Orphan Drugs Due to Exceeding the Sales Threshold in Germany - Update
Poster Session 2, 18. Nov - HTA 150
https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4014/144905
Brückel S, Elkashef B
Analysis of the Distribution of the Added Benefit Dimensions in Early Benefit Assessments Due to Label Extensions in Germany
Poster Session 3, 19. Nov - HTA 236
https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/144926
